Search Results - "Harbison, C."

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer by Jonker, D J, Karapetis, C S, Harbison, C, O'Callaghan, C J, Tu, D, Simes, R J, Malone, D P, Langer, C, Tebbutt, N, Price, T J, Shapiro, J, Siu, L L, Wong, R P W, Bjarnason, G, Moore, M J, Zalcberg, J R, Khambata-Ford, S

“…Background: Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy–refractory colorectal cancer. Epidermal growth factor…”
Get full text

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer by Baker, J B, Dutta, D, Watson, D, Maddala, T, Munneke, B M, Shak, S, Rowinsky, E K, Xu, L-A, Harbison, C T, Clark, E A, Mauro, D J, Khambata-Ford, S

“…Background: Although it is accepted that metastatic colorectal cancers (mCRCs) that carry activating mutations in KRAS are unresponsive to anti-epidermal…”
Get full text

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy by Novotny, J.F., Cogswell, J., Inzunza, H., Harbison, C., Horak, C., Averbuch, S.

“…The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with…”
Get full text

Remodeling of yeast genome expression in response to environmental changes by Causton, H C, Ren, B, Koh, S S, Harbison, C T, Kanin, E, Jennings, E G, Lee, T I, True, H L, Lander, E S, Young, R A

“…We used genome-wide expression analysis to explore how gene expression in Saccharomyces cerevisiae is remodeled in response to various changes in extracellular…”
Get full text

Strain- and Diet-Related Lesion Variability in Aging DBA/2, C57BL/6, and DBA/2xC57BL/6 F1 Mice by Harbison, C. E., Lipman, R. D., Bronson, R. T.

“…Genetic and environmental factors both play a role in the occurrence of age-related disease. To examine the genetic contribution to the development of…”
Get full text

CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti–LAG-3) in combination with nivolumab (anti–PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma by Lipson, E.J., Long, G.V., Tawbi, H., Schadendorf, D., Atkinson, V.G., Maurer, M., Simonsen, K.L., Harbison, C., Hodi, F.S.

Get full text

Immunohistochemical Characterization of Large Intestinal Adenocarcinoma in the Rhesus Macaque (Macaca mulatta) by Harbison, C. E., Taheri, F., Knight, H., Miller, A. D.

“…In rhesus macaques, adenocarcinomas of either the ileocecal junction or colon are common spontaneous tumors in aging populations. The macaque tumors have…”
Get full text

Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations by Luke, J.J., Edwards, R., Hedvat, C., Pandya, D., Ely, S., Meier, R., McDonald, D., Harbison, C.T., Baxi, V., Lee, G., Szabo, P., Garcia, T., Bao, R., Reilly, T.P., Jaffee, E., Hodi, F.S.

Get full text

Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer by Abdel-Motal, U M, Harbison, C, Han, T, Pudney, J, Anderson, D J, Zhu, Q, Westmoreland, S, Marasco, W A

“…Topical microbicides are a leading strategy for prevention of HIV mucosal infection to women; however, numerous pharmacokinetic limitations associated with…”
Get full text

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC) by Gettinger, S, Chow, L.Q, Borghaei, H, Shen, Y, Harbison, C, Chen, A.C, Rizvi, N.A

Get full text

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) by Antonia, S.J, Gettinger, S, Goldman, J, Chow, L.Q, Juergens, R, Borghaei, H, Brahmer, J.R, Shen, Y, Harbison, C, Chen, A.C, Ready, N.E, Rizvi, N.A

Get full text

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status by Rizvi, N.A, Shepherd, F.A, Antonia, S.J, Brahmer, J.R, Chow, L.Q, Goldman, J, Juergens, R, Borghaei, H, Ready, N.E, Gerber, D.E, Shen, Y, Harbison, C, Chen, A.C, Gettinger, S

Get full text

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) by Antonia, S.J, Brahmer, J.R, Gettinger, S, Chow, L.Q, Juergens, R, Shepherd, F.A, Laurie, S.A, Gerber, D.E, Goldman, J, Shen, Y, Harbison, C, Chen, A.C, Borghaei, H, Rizvi, N.A

Get full text

Transcriptional Regulatory Networks in Saccharomyces cerevisiae by Lee, Tong Ihn, Rinaldi, Nicola J., Robert, François, Odom, Duncan T., Bar-Joseph, Ziv, Gerber, Georg K., Hannett, Nancy M., Harbison, Christopher T., Thompson, Craig M., Simon, Itamar, Zeitlinger, Julia, Jennings, Ezra G., Murray, Heather L., Gordon, D. Benjamin, Ren, Bing, Wyrick, John J., Tagne, Jean-Bosco, Volkert, Thomas L., Fraenkel, Ernest, Gifford, David K., Young, Richard A.

“…We have determined how most of the transcriptional regulators encoded in the eukaryote Saccharomyces cerevisiae associate with genes across the genome in…”
Get full text

Serial Regulation of Transcriptional Regulators in the Yeast Cell Cycle by Simon, Itamar, Barnett, John, Hannett, Nancy, Harbison, Christopher T, Rinaldi, Nicola J, Volkert, Thomas L, Wyrick, John J, Zeitlinger, Julia, Gifford, David K, Jaakkola, Tommi S, Young, Richard A

“…Genome-wide location analysis was used to determine how the yeast cell cycle gene expression program is regulated by each of the nine known cell cycle…”
Get full text

Meeting Report: Spontaneous Lesions and Diseases in Wild, Captive-Bred, and Zoo-Housed Nonhuman Primates and in Nonhuman Primate Species Used in Drug Safety Studies by Sasseville, V. G., Mansfield, K. G., Mankowski, J. L., Tremblay, C., Terio, K. A., Mätz-Rensing, K., Gruber-Dujardin, E., Delaney, M. A., Schmidt, L. D., Liu, D., Markovits, J. E., Owston, M., Harbison, C., Shanmukhappa, S., Miller, A. D., Kaliyaperumal, S., Assaf, B. T., Kattenhorn, L., Macri, S. Cummings, Simmons, H. A., Baldessari, A., Sharma, P., Courtney, C., Bradley, A., Cline, J. M., Reindel, J. F., Hutto, D. L., Montali, R. J., Lowenstine, L. J.

“…The combination of loss of habitat, human population encroachment, and increased demand of select nonhuman primates for biomedical research has significantly…”
Get full text

Characterization of cancer risk from airborne benzene exposure by Johnson, Giffe T., Harbison, Stephen C., McCluskey, James D., Harbison, Raymond D.

“…Airborne benzene is a ubiquitous environmental air pollutant. However, research regarding ambient environmental benzene exposures and leukemogenesis is…”
Get full text

Meeting Report: Emerging Respiratory Viral Infections and Nonhuman Primate Case Reports by Sasseville, V. G., Mankowski, J. L., Baldessari, A., Harbison, C., Laing, S., Kaliyaperumal, S., Mätz-Rensing, K., Miller, A. D., Schmidt, L. D., Kaplan-Kees, J., Dick, E. J., Reader, J. R., Liu, D., Crawford, L. K., Lane, J. H., Corner, S. M., Pardo, I. D., Evans, M. G., Murnane, R., Terio, K. A.

“…A workshop on Emerging Respiratory Viral Infections and Spontaneous Diseases in nonhuman primates was sponsored by the concurrent Annual Meetings of the…”
Get full text

Program-Specific Distribution of a Transcription Factor Dependent on Partner Transcription Factor and MAPK Signaling by Zeitlinger, Julia, Simon, Itamar, Harbison, Christopher T., Hannett, Nancy M., Volkert, Thomas L., Fink, Gerald R., Young, Richard A.

“…Specialized gene expression programs are induced by signaling pathways that act on transcription factors. Whether these transcription factors can function in…”
Get full text

Occupational health surveillance: Pulmonary function testing in emergency responders by McCluskey, James D, Harbison, Stephen C, Johnson, Giffe T, Xu, Ping, Morris, Steve, Wolfson, Jay, Harbison, Raymond D

“…Emergency responders may be exposed to a variety of fumes, gases, and particulates during the course of their job that can affect pulmonary function (PF) and…”
Get full text